Skip to content

Advertisement

  • Review Article
  • Open Access

Reactive oxygen species in organ-specific autoimmunity

Autoimmunity Highlights20167:11

https://doi.org/10.1007/s13317-016-0083-0

  • Received: 30 June 2016
  • Accepted: 26 July 2016
  • Published:

Abstract

Reactive oxygen species (ROS) have been extensively studied in the induction of inflammation and tissue damage, especially as it relates to aging. In more recent years, ROS have been implicated in the pathogenesis of autoimmune diseases. Here, ROS accumulation leads to apoptosis and autoantigen structural changes that result in novel specificities. ROS have been implicated not only in the initiation of the autoimmune response but also in its amplification and spreading to novel epitopes, through the unmasking of cryptic determinants. This review will examine the contribution of ROS to the pathogenesis of four organ specific autoimmune diseases (Hashimoto thyroiditis, inflammatory bowel disease, multiple sclerosis, and vitiligo), and compare it to that of a better characterized systemic autoimmune disease (rheumatoid arthritis). It will also discuss tobacco smoking as an environmental factor endowed with both pro-oxidant and anti-oxidant properties, thus capable of differentially modulating the autoimmune response.

Keywords

  • Reactive oxygen species (ROS)
  • Oxidative stress
  • Autoimmunity
  • Hashimoto thyroiditis
  • Monoamine oxidase (MAO)
  • Smoking

Introduction

Reactive oxygen species (ROS), also known as free radicals, were first described by Fenton in 1894 [1] and then studied since the mid 1950s for their involvement in aging and age-related conditions [2]. In more recent years, ROS were shown to play a role in physiological processes [3] (such as the synthesis of thyroid hormones and proliferation of thyroid follicular cells [4]), in cellular signaling as second messengers [5], in the normal response of phagocytes to intracellular pathogens, and in a variety of pathological conditions ranging from sarcopenia [6] to cancer [7].

Oxygen is activated by the addition of electron(s) donated by a variety of substances. This transfer of electrons from a substance (reductant) to another one (oxidant) is called redox reaction, a highly conserved reaction that leads to the production of ROS. There are three major ROS: superoxide anion, hydrogen peroxide, and hydroxyl radical (Fig. 1, boxed).
Fig. 1
Fig. 1

Schematic representation of the three major reactive oxygen species (superoxide, hydrogen peroxide, and hydroxyradical) and the enzymatic pathways that produce them. NADH nicotinamide adenine dinucleotide, NADPH nicotinamide adenine dinucleotide phosphate, GSH glutathione, GSSG glutathione disulfide, SOD superoxide dismutase, NOS nitric oxide synthases, MAO monoamine oxidase, MPO myeloperoxidase

Addition of one electron to molecular oxygen leads to the production of superoxide anion (O 2 −· ), the precursor of the other two ROS. In fact, superoxide anion can dismutate spontaneously to produce hydrogen peroxide by the addition of another electron and two protons, or be converted enzymatically by the cytosolic superoxide dismutase 1 and the mitochondrial superoxide dismutase 2 (Fig. 1). Hydrogen peroxide (H2O2), a stable ROS, then diffuses through lipid bilayers or intramembranous aquaporins [8], and likely represents the dominant ROS involved in redox signaling due to its stability. Through the classic Fenton reaction (based on the reduction of transition metals, for example from Fe2+ to Fe3+), H2O2 is then split into hydroxyl radical (OH·) and a hydroxide ion. Hydroxyl radicals are highly reactive and exist for only a microsecond, resulting in an oxidative damage that localizes to the site where they are produced [9]. Hydroxyl radicals can also be formed directly from superoxide anion in the presence of hydrogen peroxide through the Haber–Weiss reaction (Fig. 1).

Several additional molecules can be produced from the three main ROS described above. For example, H2O2 in the presence of a chloride anion is converted by myeloperoxidase into hypochlorous acid, a species important for destroying pathogens within the phagocytic compartment of immune cells [10]. Superoxide can also react with nitric oxide to produce a highly reactive peroxynitrite species (Fig. 1).

This cellular production of ROS is counterbalanced by the presence of numerous molecular and enzymatic antioxidants. Molecules that work as anti-oxidant include vitamins C, A and E, uric acid, glutathione, pycnogenol, and thioredoxin [11]. Antioxidant enzymes include catalase, thioredoxin reductase, glutathione peroxidase, glutathione reductase, glutathione S-transferase, ascorbate peroxidase, ascorbate reductase, and glucose-6-phosphate dehydrogenase [12]. Catalase neutralizes two hydrogen peroxide equivalents into two waters and one molecular oxygen (Fig. 1). On the other hand, glutathione peroxidase uses glutathione as a reducing agent to generate two water equivalents from one hydrogen peroxide species (Fig. 1). To regenerate the pool of glutathione, glutathione reductase converts nicotinamide adenine dinucleotide phosphate to its oxidized form, return oxidized glutathione into its reduced form [13, 14].

Cellular sources that produce ROS

There are three major intracellular sources of ROS: electron leak from the mitochondrial respiratory chain, NADPH oxidases, and uncoupled nitric oxide synthase reactions (Fig. 2). ROS can also be generated by monoamine oxidase, and other oxidases such as xanthine oxidase, lipoxygenases, cyclooxygenases, and monooxygenases.
Fig. 2
Fig. 2

Representation of the main cellular locations where ROS are produced. The abbreviations are the same as those used in Fig. 1, plus the following: Nox non-phagocytic NADPH oxidase, AQP aquaporin, GPx glutathione peroxidase, GR glutathione reductase, mPTP mitochondrial permeability transition pore, FAD flavin adenine dinucleotide, FADH2 flavin adenine dinucleotide

Electron leak from the mitochondrial respiratory chain

Mitochondria generate about 90 % of all ROS [15] during the process of ATP production. This process, called oxidative phosphorylation, is driven by the electron transport chain, which consists of five protein complexes located on the inner mitochondrial membrane (Fig. 2, box). The first four complexes utilize oxygen and high-energy electrons to generate a proton gradient in the intermembrane space. The gradient then provides the energy needed to drive the production of ATP by complex. During cellular stress, electrons leak from the respiratory chain and react with molecular oxygen to generate superoxide anion and the secondary ROS [15], which then leave the mitochondria through the permeability transition pore located on the outer membrane [16].

Complex 1, 2, and 3 are the primary sites for ROS production [17], although other factors such as the ratio of ubiquinol to ubiquinone, the mitochondrial membrane potential, and the proton-motive force may be involved [15]. Complex 1 can reduce oxygen to superoxide on the leaflet facing the mitochondrial matrix, and contains a Q-binding site, a flavin mononucleotide, and multiple iron-sulfur clusters that directly participate in ROS production [15, 18]. Complex 2 can alter its catalytic activity to modulate directionality of the electron transport chain to promote ROS production [19], especially when complex 1 or 3 is impaired [20]. Alternative sources of mitochondrial ROS may result from cytochrome C electron transfer to p66-Shc, which subsequently transfers electrons to oxygen in the intermembrane space to generate both superoxide and hydrogen peroxide [21]. Complex 3 transfers electrons from ubiquinol to cytochrome C and mostly generates ROS at the Q-binding site, which diffuses into both the matrix and intermembrane space [15].

NADPH oxidase

Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase is a flavocytochrome originally discovered in phagocytes. Its function is to release superoxide or hydrogen peroxide in the phagocytic compartment to neutralize pathogens. NADPH oxidase generates superoxide by the catalytic transfer of high energy electrons from the nicotinamide moiety of NADPH to flavin adenine dinucleotide, and then to molecular oxygen.

Phagocytic NADPH oxidase is an assembly of membrane-bound p22 oxidase (p22phox), gp91phox catalytic subunit, and at least four other cytosolic subunits: p47phox, p40phox, p67phox, and a small G-protein Rac or p21 Rac [22]. Non-phagocytic NADPH oxidase (abbreviated as Nox) refers to homologues of the catalytic gp91 subunit found in non-phagocytic cells [23]. They have similar structure to the phagocytic NAPDH but different biological functions. They are found in endothelial cells and fibroblasts and respond to pro-inflammatory cytokines such as tumor necrosis factor alpha by enhancing superoxide production [2427], although less efficiently than the phagocytic form. There are seven Nox isotypes (Nox 1 through 5, dual oxidase 1, and dual oxidase 2), mostly localized to the plasma membrane [28]. They generate ROS on the cytosolic leaflet of the plasma membrane or release them into the extracellular milieu, as Nox-containing vesicles fuse with the plasma membrane during Nox activation [28]. ROS produced in this fashion can in turn inhibit Nox to maintain a low basal oxidative state or upregulate it in a feed-forward mechanism [13, 29, 30]. Nox-derived ROS are involved in apoptosis and fibrosis of various tissues [31].

Uncoupled nitric oxide synthase reactions

Nitric oxide synthase (NOS) converts l-arginine into citrulline, using tetra-hydro-biopterin as cofactor, as well as other substrates. This reaction releases nitric oxide (NO·) (Fig. 1), an important gas that mediates vasodilation and is involved in numerous other functions, such as the immune response against parasites [32]. There are three main types of NOS: neuronal, endothelial, and inducible. If substrates become limiting or unusable, the reaction uncouples generating large amounts of superoxide, which then reacts with nitric oxide to generate peroxynitrite [10] (Fig. 1), a substance that negates the important vasodilatory effect of nitric oxide. ROS can damage nitric oxide synthase and induce more ROS production in a feed-forward mechanism fashion, promoting in this case endothelial apoptosis, hyper coagulation, and monocyte adhesion [33].

Monoamine oxidase

Monoamine oxidase (MAO) is located on the cytosolic leaflet of the outer membrane of mitochondria and mediates the catabolism of monoamine neurotransmitters. There are two well-characterized isotypes of MAO that differ because of their substrate specificity: MAO-A predominantly catabolizes serotonin and noradrenaline, while MAO-B preferentially deaminates phenylethylamine and benzylamine. Dopamine and tyramine are metabolized similarly by both MAO isoforms. MAO isoforms are expressed in several other tissues besides the nervous system: cardiomyocytes, hepatocytes, duodenal villi, vessels, renal collecting tubules, and Bowman’s capsule [34]. In the pancreatic islets, MAO-B is expressed in beta and alpha cells and negatively regulates insulin secretion [35]. MAO contribute to ROS production mainly through the synthesis of H2O2 [36] (Fig. 2).

Inhibition of MAO, and thus inhibition of neurotransmitter degradation, represented the first pharmacological treatment developed for depression in the early 1950s. More recently, MAO inhibitors are being used in other conditions because of their ability to decrease ROS production. For example, Kalurdercic and colleagues identified MAO-derived hydrogen peroxide as a contributor to cardiac damage in ischemia reperfusion injury, and proposed MAO inhibitors as a treatment for this condition [37]. Recently, MAO-derived ROS have been linked to cardiomyocyte necrosis and heart failure by impairing activation of transcription factor-EC activation and mitochondria clearance by lysosomes [38]. In the field of autoimmunity, it has been shown that the MAO inhibitor phenelzine ameliorates disease outcomes in a mouse model of multiple sclerosis [39]. Furthermore, phenytoin, an anticonvulsant that inhibits norepinephrine release and MAO activity, induces proliferation in cultured melanocytes and has therefore, been proposed as a treatment for vitiligo [40].

ROS in autoimmune diseases

The role of ROS in autoimmunity is complex. The traditional view holds that ROS accumulation is detrimental to the autoimmune disease process. Oxidative stress ensues when the production of ROS surpasses the buffering capacity of the endogenous antioxidants [41], leading to oxidation of lipids in the plasma membrane, proteins in cytosol and nucleus, and nucleic acids that overall damage the cells in the organ targeted by autoimmunity. Oxidative stress can also lead to the generation of novel autoantigens and thus exacerbation of the autoimmune response [42]. In keeping with these findings, ROS production has been linked directly to inflammation via the production of TNF-α: Salzano et al. reported that macrophages release an oxioreductase that directly stimulates TNF-α [43]. But more recent studies reveal a regulatory role of ROS where they prevent progression of chronic inflammatory responses (reviewed in [44]).

Two excellent reviews have been published on the role of ROS in systemic autoimmune and inflammatory diseases [45, 46]. We will discuss here the contribution of ROS to four organ-specific autoimmune diseases, comparing it to that reported in rheumatoid arthritis, and use tobacco smoking as an example of an environmental factor that can function both as an oxidant and anti-oxidant.

ROS and Hashimoto thyroiditis

As mentioned in the introduction, ROS are fundamental for the normal functioning of the thyroid follicular cell. ROS, however, have also been implicated in the pathogenesis of Hashimoto thyroiditis, in both murine and human models.

The NOD-H2h4 mouse is a congenic strain that develops autoimmune thyroiditis spontaneously but at a low incidence, an incidence that can, however, be significantly increased by addition of iodine to the drinking water [47, 48]. Burek and colleagues showed that thyrocytes isolated from NOD-H2h4 mice produced significantly more H2O2 than control thyrocytes when exposed to iodine [49]. They also associated this increased ROS load with higher expression of intracellular adhesion molecule-1 on thyrocytes [50], and therefore, with greater retention capacity of the lymphocytes that infiltrate the thyroid gland. Incubation with the antioxidant diphenyleneiodium, an inhibitor of NADPH oxidase, reduced ROS generation and adhesion molecule expression in cultured NOD-H2h4 thyrocytes [50]. Kolypetri and Carayanniotis showed that ROS increase the apoptosis of NOD-H2h4 thyrocytes exposed to iodine [51]. Thyroidal accumulation of ROS has also been shown to promote cleavage of thyroglobulin into several fragments, likely exposing the immune system to novel epitopes and thus enhancing the autoimmune response [52]. Finally, increased content of 4-HNE, a toxic product from lipid peroxidation used as a marker of oxidative stress, was found in NOD.H2h4 thyroid glands [53]. Overall, studies in the NOD.H2h4 model suggest that thyroidal accumulation of ROS contributes to the initiation and progression of autoimmune thyroiditis.

Studies in patients with Hashimoto thyroiditis are more limited. Ates and colleagues compared 93 cases with Hashimoto thyroiditis (a third in each of the euthyroid, subclinical hypothyroidism, and overt hypothyroidism subgroups), to 31 healthy controls. They found that oxidative stress parameters in the peripheral blood were higher in cases than controls, particularly in the overt hypothyroidism group [54]. In a smaller study of 35 euthyroid Hashimoto cases and 35 healthy controls, Baser et al. reported that serum oxidant status was higher in cases than controls, and positively correlated with the levels of thyroglobulin antibodies [55]. Finally, Ruggieri et al. analyzed 71 euthyroid Hashimoto thyroiditis cases and 63 healthy controls, reporting that oxidative stress is higher in cases and that thyroperoxidase antibodies are the main predictor of the oxidative status independent of thyroid function [56]. Overall, human studies report an increased oxidative status in Hashimoto thyroiditis but do not clarify whether this is the cause or result of thyroid dysfunction.

ROS and inflammatory bowel disease

Increased levels of ROS have been reported throughout the colon of patients with inflammatory bowel disease. The increase is not limited to areas of active inflammation, thus suggesting a role for oxidative stress during the early phases of disease pathogenesis [57]. Interestingly, because of the high rate of depression in inflammatory bowel disease, MAO inhibitors are commonly prescribed in this patient population [58]. In a review of studies examining the effectiveness of antidepressants, the MAO inhibitor phenelzine improved both psychiatric and somatic symptoms of inflammatory bowel disease [59]. In addition, numerous case reports have documented clinical improvement or remission of the bowel inflammation upon usage of phenelzine [59, 60]. The normal colon is the organ that, after the placenta, expresses the highest levels of MAO-A, and it is reasonable to postulate that these levels increase even further upon inflammation. Indeed, Magro and colleagues identified markedly lower levels of monoamines in the mucosa of ulcerative colitis patients, suggesting MAO hyperactivity and consequently increased ROS production [61]. Although no study has directly assessed the link between MAO activity and ROS levels in gut mucosa, or their temporal relationship with bowel inflammation, we suggest that MAO inhibition exerts its beneficial effects in ulcerative colitis by lowering the levels of ROS.

ROS and multiple sclerosis

Given the high levels of oxidative activity found in neurological tissues, it is not surprising that ROS have long been associated with the pathological damage typical of multiple sclerosis [62]. Indeed, several oxidized molecules can potentially be used as diagnostic biomarkers [63]. Increased levels of peroxynitrite are found in active multiple sclerosis lesions [64]. ROS have also been implicated in the dysregulation of the blood–brain barrier, which results in faster disease progression due to increased monocyte infiltration and inflammation [65]. By proteomics, Fiorini and colleagues have shown that patients with the relapsing-remitting form of multiple sclerosis have higher levels of oxidized proteins than healthy controls [66]. Ceruloplasmin, antithrombin III, clusterin, apolipoprotein E, and complement C3, were upregulated in cases; vitamin D-binding protein showed an increasing trend toward oxidation in patients going from remission to relapse. Using a whole-genome microarray approach, Fischer et al. found that several mitochondrial genes involved in inducing oxidative stress were upregulated in multiple sclerosis patients [67]. They also found that microglial cells and astrocytes upregulated the p22 subunit of the Nox2 complex within active pathological lesions. These findings suggest that ROS are involved in early disease stages of multiple sclerosis, when myelin sheaths are still intact but there is lymphocytic infiltration and microglial activation [65, 67].

ROS and vitiligo

In patients with vitiligo the epidermis contains increased levels of ROS, mainly H2O2 and peroxynitrite, as well as inadequate antioxidant defenses [68]. This ROS increase originates from several sources, both exogenous (ultraviolet radiations, trauma, stress, infections, malignancies, certain drugs) and endogenous. First, there is an elevated activity of NADPH oxidase and NOS, with secondary increase production of ROS and reactive nitrogen species [69] (Fig. 1). Then, there is an accumulation of tetra-hydro-biopterin, an essential cofactor for the aromatic amino acid hydroxylases and NOS. Increased biopterin levels boost the formation of H2O2 and inhibit the function of phenylalanine and tyrosine hydroxylases, thus impairing melanin production in melanocytes and inducing norepinephrine accumulation in keratinocytes [70]. Finally, there is an increased activity of MAO-A, which leads to the accumulation of toxic levels of H2O2 [71], and a largely impaired mitochondrial function [72]. Low levels of antioxidants, such as catalase, glutathione peroxidase, glucose-6-phosphate dehydrogenase, superoxide dismutase, and vitamins C and E have been reported in the epidermis and serum of vitiligo patients [7375]. Recently, Jian and colleagues have shown that the anti-oxidant response element nuclear factor E2 protects melanocytes from H2O2 damage through the induction of antioxidant genes, such as heme oxygenase-1, and that this pathway is functionally deficient in vitiligo melanocytes, rendering them more susceptible to oxidative stress [76, 77].

Increased skin content of ROS not only directly damages the melanocytes but also induces an autoimmune response against them. In fact, ROS modify the structure of key vitiligo autoantigens such as melan A and tyrosinase, leading to the formation of novel epitopes which then trigger autoreactivity. During the early stages of vitiligo, lipid peroxidation levels, a marker of oxidative stress, have been reported to be increased, whereas melanocyte antibodies appear in later disease stages [72], suggesting that ROS play a role in initiating vitiligo and amplifying the loss of melanocytes.

ROS and rheumatoid arthritis

Oxidative stress plays an important role in the pathogenesis of rheumatoid arthritis [78]. Staroń and colleagues analyzed erythrocytes from rheumatoid arthritis cases and healthy controls and reported increased lipid peroxidation, decreased activity of antioxidant enzymes, and decreased sodium–potassium ATPase functions [79]. In the synovial cavity, Mapp et al. have found increased ROS content, leading to the oxidation of immunoglobulins, mainly IgM, recognizing the Fc portion of IgG (so called, rheumatoid factor), lipoproteins, lipids, and hyaluronan [80]. Immunoglobulins damaged by oxidation are more sensitive to non-enzymatic degradation by sugars, primarily at arginine and lysine residues, leading to the formation of advanced glycation end products [78], as it is seen in diabetes mellitus where prolonged hyperglycemia glycoxidates hemoglobin into hemoglobin A1c. Indeed, antibodies to glycoxidized IgG are specifically found in patients with early synovitis [81]. Increased ROS also damage the DNA mismatch repair system, which is defective in rheumatoid arthritis, and the DNA itself, resulting in elevated concentrations of 8-oxo-7-hydro-deoxyguanosine [78]. Further tissue damage originates from ROS produced by monocytes and neutrophils [82]. Neutrophils degranulate in the synovial joint releasing myeloperoxidase that, using chloride and H2O2, catalyzes the formation of hypochlorous acid (Fig. 1). Hypochlorous acid is a very strong oxidant: it mainly reacts with methionines and cysteines disrupt protein tertiary structure and activity [83]. In keeping with a pathogenic role of ROS, rheumatoid arthritis patients who improve upon treatment with monoclonal antibodies that block tumor necrosis factor alpha do show reduced plasma levels of ROS [84].

Animal models of rheumatoid arthritis have been used to assess the potential therapeutic benefits of anti-oxidant administration. In the adjuvant-induced rat model of the disease, paeoniflorin significantly improved the arthritic symptoms and increased the pain threshold, changes that were associated with boosted activity of the anti-oxidant enzymes catalase and glutathione peroxidase [85]. In the collagen-induced rat model of arthritis, administration of the antioxidant thymoquinone improved arthritis scoring and bone histopathology while reducing pro-inflammatory cytokines and ROS content [86].

Tobacco smoke as a modulator of the oxidants/anti-oxidants balance

Tobacco smoke contains a variety of ROS, reactive nitrogen species, and other compounds that increase the burden of oxidative stress [87]. It is unquestionable that smoking has deleterious effects on human health, most notably related to a higher risk of chronic respiratory diseases [77, 88, 89] and cancer [90, 91]. Intriguingly, however, smoking can also be beneficial in a selected group of conditions, for example in patients with ulcerative colitis [9295], Hashimoto thyroiditis (see Supplemental Table 1 in [96]), and Parkinson disease [97, 98]. In addition, it is known that small amounts of ROS protect the myocardium from hypoxic damage, in a process termed ischemic preconditioning [99]. It is thus possible that ROS acquired from cigarette smoking precondition organs targeted by autoimmunity by inducing some measures of protection. An excellent review on the varied effect of smoking in autoimmune diseases has been recently published [100]. Here, we will focus on the pro-oxidant and anti-oxidant effects of smoking, using autoimmune thyroiditis as an example.

Pro-oxidant effects of smoking

ROS in smoking cause oxidative damage to DNA, as indicated by increased urinary levels of 8-hydroxy-2′-deoxyguanosine [101]. Similarly, bronchoalveolar lavage fluid levels of this molecule positively correlate with smoking status [102]. Smoking also contains reactive nitrogen species [77] and thiocyanate that, despite operating through different mechanisms, also leads to increased oxidation in certain organs. Thiocyanate, in fact, competitively inhibits the uptake of iodine by the sodium-iodide symporter, thus reducing the concentration of iodine inside the thyroid cell and possibly leading to higher oxidative load [103].

Some carcinogens generated during the combustion of tobacco contribute to oxidation. For example, 2-amino-9H-pyrido [2,3-b]indole (abbreviated as AαC) becomes activated in vivo to form N-oxidized metabolites that covalently bind to DNA (DNA adducts) and albumin (albumin adducts), promoting mutations and loss of function [104]. Normal albumin, the most abundant protein in human serum, normally serves as an anti-oxidant because it scavenges ROS generated during cell metabolism or introduced from the environment. Albumin adducts loose this protective property.

Anti-oxidant effects of smoking

Tobacco leaves contain compounds that inhibit the activity of MAO, and thus reduce the amount of ROS produced by these enzymes. Smokers are known to have lower MAO activity than non-smokers. For example, positron emission tomography brain scans using 11C-based tracers that bind to catalytically active MAO have demonstrated a reduced MAO activity in smokers [105, 106]. More specifically, [11C]clorgyline, a potent and irreversible inhibitor of MAO-A, showed a mean 28 % reduction in MAO-A activity (ranging from 22 to 38 %) across all cortical and subcortical regions imaged [105]. Similarly, using [11C]befloxatone, which also binds MAO-A reversibly, there was a 60 % average reduction in smokers in cortical regions [106]. Different tracers or earlier scans (within 2 h from the last cigarette smoked) could explain the different percent inhibitions observed in the two studies [107].

What are the compounds in cigarette smoking that inhibit the activity of MAOs? Likely many and their presence is perhaps a reason why smokers have difficulty quitting: MAO inhibition, in fact, could provide a pleasant anti-depressant effect, although no solid data support this hypothesis [108]. Trans–trans-farnesol and 2,3,6-trimethyl-1,4-naphthoquinone specifically inhibit MAO-B [109]; β-carboline alkaloids inhibit MAO-A and MAO-B [106]. Nicotine, the major tobacco alkaloid, could also have MAO inhibitory properties. Recently, it has been in fact shown that nicotine chelates ferrous ion (Fe2+) in a concentration-dependent fashion. Since Fe2+ can produce ·OH through the Fenton reaction (Fig. 1), these results support a role for nicotine and related alkaloids as antioxidants [110].

Collectively, these results demonstrate that in the highly complex mixture of chemicals characteristic of tobacco smoke there are compounds that have pro-oxidant, antioxidant, or both kinds of properties. Future studies that examining the oxidation status globally, rather than selectively focusing on oxidative or antioxidant effects, could help unravel the overall role of smoking tobacco with regard to oxidation.

Conclusions

The role of ROS in autoimmunity remains complex. ROS accumulation has been implicated both in the initiation and progression of autoimmunity, but is still unclear whether it represents a bona fide trigger or a harmless accompaniment. It is, however, intriguing to consider the development of selective ROS inhibitors as a tool that could be used to treat a broad spectrum of autoimmune diseases.

Abbreviations

ROS: 

Reactive oxygen species

NADPH: 

Nicotinamide adenine dinucleotide phosphate

NOS: 

Nitric oxide synthase

MAO: 

Monoamine oxidase

Declarations

Acknowledgments

The study was supported by patient donations to the Johns Hopkins Hypophysitis and Autoimmune Disease Research Centers.

Compliance with ethical standards

Conflict of interest

Giulia Di Dalmazi, Jason Hirshberg, Daniel Lyle, Joudeh B. Freij, and Patrizio Caturegli declare that they have no conflict of interest.

Human and animal rights

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

This is a review article and therefore, Informed Consent from patients is not necessary.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors’ Affiliations

(1)
Division of Immunology, Department of Pathology, The Johns Hopkins School of Medicine, Baltimore, MD 21205, USA
(2)
Department of Medicine, G. D’Annunzio University of Chieti, Chieti, Italy
(3)
Department of Biochemistry and Molecular Biology, The Johns Hopkins School of Public Health, Baltimore, MD, USA
(4)
Department of Molecular Microbiology and Immunology, The Johns Hopkins School of Public Health, Baltimore, MD, USA

References

  1. Fenton HJJ (1894) Oxidation of tartaric acid in presence of iron. J Chem Soc 65:899–910View ArticleGoogle Scholar
  2. Harman D (1956) Aging: a theory based on free radical and radiation chemistry. J Gerontol 11(3):298–300PubMedView ArticleGoogle Scholar
  3. Droge W (2002) Free radicals in the physiological control of cell function. Physiol Rev 82(1):47–95. doi:10.1152/physrev.00018.2001 PubMedView ArticleGoogle Scholar
  4. Poncin S, Van Eeckoudt S, Humblet K, Colin IM, Gerard AC (2010) Oxidative stress: a required condition for thyroid cell proliferation. Am J Pathol 176(3):1355–1363. doi:10.2353/ajpath.2010.090682 PubMedPubMed CentralView ArticleGoogle Scholar
  5. Wang X, Hai C (2016) Novel insights into redox system and the mechanism of redox regulation. Mol Biol Rep. doi:10.1007/s11033-016-4022-y Google Scholar
  6. Jackson MJ (2016) Reactive oxygen species in sarcopenia: should we focus on excess oxidative damage or defective redox signalling? Mol Asp Med. doi:10.1016/j.mam.2016.05.002 Google Scholar
  7. Panieri E, Santoro MM (2016) ROS homeostasis and metabolism: a dangerous liason in cancer cells. Cell Death Dis 7(6):e2253. doi:10.1038/cddis.2016.105 PubMedView ArticleGoogle Scholar
  8. Miller EW, Dickinson BC, Chang CJ (2010) Aquaporin-3 mediates hydrogen peroxide uptake to regulate downstream intracellular signaling. Proc Natl Acad Sci USA 107(36):15681–15686. doi:10.1073/pnas.1005776107 PubMedPubMed CentralView ArticleGoogle Scholar
  9. Hippeli S, Elstner EF (1999) Transition metal ion-catalyzed oxygen activation during pathogenic processes. FEBS Lett 443(1):1–7PubMedView ArticleGoogle Scholar
  10. Taniyama Y, Griendling KK (2003) Reactive oxygen species in the vasculature: molecular and cellular mechanisms. Hypertension 42(6):1075–1081. doi:10.1161/01.hyp.0000100443.09293.4f PubMedView ArticleGoogle Scholar
  11. Karlenius TC, Tonissen KF (2010) Thioredoxin and cancer: a role for thioredoxin in all states of tumor oxygenation. Cancers 2(2):209–232. doi:10.3390/cancers2020209 PubMedPubMed CentralView ArticleGoogle Scholar
  12. Wang X, Tao L, Hai CX (2012) Redox-regulating role of insulin: the essence of insulin effect. Mol Cell Endocrinol 349(2):111–127. doi:10.1016/j.mce.2011.08.019 PubMedView ArticleGoogle Scholar
  13. Li JM, Shah AM (2003) ROS generation by nonphagocytic NADPH oxidase: potential relevance in diabetic nephropathy. J Am Soc Nephrol JASN 14(8 Suppl 3):S221–S226PubMedView ArticleGoogle Scholar
  14. Allen DG, Lamb GD, Westerblad H (2008) Skeletal muscle fatigue: cellular mechanisms. Physiol Rev 88(1):287–332. doi:10.1152/physrev.00015.2007 PubMedView ArticleGoogle Scholar
  15. Balaban RS, Nemoto S, Finkel T (2005) Mitochondria, oxidants, and aging. Cell 120(4):483–495. doi:10.1016/j.cell.2005.02.001 PubMedView ArticleGoogle Scholar
  16. Hausenloy D, Wynne A, Duchen M, Yellon D (2004) Transient mitochondrial permeability transition pore opening mediates preconditioning-induced protection. Circulation 109(14):1714–1717. doi:10.1161/01.cir.0000126294.81407.7d PubMedView ArticleGoogle Scholar
  17. Pitkanen S, Robinson BH (1996) Mitochondrial complex I deficiency leads to increased production of superoxide radicals and induction of superoxide dismutase. J Clin Investig 98(2):345–351. doi:10.1172/jci118798 PubMedPubMed CentralView ArticleGoogle Scholar
  18. Treberg JR, Quinlan CL, Brand MD (2011) Evidence for two sites of superoxide production by mitochondrial NADH-ubiquinone oxidoreductase (complex I). J Biol Chem 286(31):27103–27110. doi:10.1074/jbc.M111.252502 PubMedPubMed CentralView ArticleGoogle Scholar
  19. Paddenberg R, Ishaq B, Goldenberg A, Faulhammer P, Rose F, Weissmann N, Braun-Dullaeus RC, Kummer W (2003) Essential role of complex II of the respiratory chain in hypoxia-induced ROS generation in the pulmonary vasculature. Am J Physiol Lung Cell Mol Physiol 284(5):L710–L719. doi:10.1152/ajplung.00149.2002 PubMedView ArticleGoogle Scholar
  20. Quinlan CL, Orr AL, Perevoshchikova IV, Treberg JR, Ackrell BA, Brand MD (2012) Mitochondrial complex II can generate reactive oxygen species at high rates in both the forward and reverse reactions. J Biol Chem 287(32):27255–27264. doi:10.1074/jbc.M112.374629 PubMedPubMed CentralView ArticleGoogle Scholar
  21. Giorgio M, Migliaccio E, Orsini F, Paolucci D, Moroni M, Contursi C, Pelliccia G, Luzi L, Minucci S, Marcaccio M, Pinton P, Rizzuto R, Bernardi P, Paolucci F, Pelicci PG (2005) Electron transfer between cytochrome c and p66Shc generates reactive oxygen species that trigger mitochondrial apoptosis. Cell 122(2):221–233. doi:10.1016/j.cell.2005.05.011 PubMedView ArticleGoogle Scholar
  22. Babior BM, Lambeth JD, Nauseef W (2002) The neutrophil NADPH oxidase. Arch Biochem Biophys 397(2):342–344. doi:10.1006/abbi.2001.2642 PubMedView ArticleGoogle Scholar
  23. Lambeth JD, Cheng G, Arnold RS, Edens WA (2000) Novel homologs of gp91phox. Trends Biochem Sci 25(10):459–461PubMedView ArticleGoogle Scholar
  24. Zalba G, San Jose G, Moreno MU, Fortuno MA, Fortuno A, Beaumont FJ, Diez J (2001) Oxidative stress in arterial hypertension: role of NAD(P)H oxidase. Hypertension 38(6):1395–1399PubMedView ArticleGoogle Scholar
  25. Radeke HH, Cross AR, Hancock JT, Jones OT, Nakamura M, Kaever V, Resch K (1991) Functional expression of NADPH oxidase components (alpha- and beta-subunits of cytochrome b558 and 45-kDa flavoprotein) by intrinsic human glomerular mesangial cells. J Biol Chem 266(31):21025–21029PubMedGoogle Scholar
  26. Jones SA, Hancock JT, Jones OT, Neubauer A, Topley N (1995) The expression of NADPH oxidase components in human glomerular mesangial cells: detection of protein and mRNA for p47phox, p67phox, and p22phox. J Am Soc Nephrol JASN 5(7):1483–1491PubMedGoogle Scholar
  27. Griendling KK, Sorescu D, Ushio-Fukai M (2000) NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 86(5):494–501PubMedView ArticleGoogle Scholar
  28. Brown DI, Griendling KK (2009) Nox proteins in signal transduction. Free Radic Biol Med 47(9):1239–1253. doi:10.1016/j.freeradbiomed.2009.07.023 PubMedPubMed CentralView ArticleGoogle Scholar
  29. Li WG, Miller FJ Jr, Zhang HJ, Spitz DR, Oberley LW, Weintraub NL (2001) H(2)O(2)-induced O(2) production by a non-phagocytic NAD(P)H oxidase causes oxidant injury. J Biol Chem 276(31):29251–29256. doi:10.1074/jbc.M102124200 PubMedPubMed CentralView ArticleGoogle Scholar
  30. Kovacic HN, Irani K, Goldschmidt-Clermont PJ (2001) Redox regulation of human Rac1 stability by the proteasome in human aortic endothelial cells. J Biol Chem 276(49):45856–45861. doi:10.1074/jbc.M107925200 PubMedView ArticleGoogle Scholar
  31. Maejima Y, Kuroda J, Matsushima S, Ago T, Sadoshima J (2011) Regulation of myocardial growth and death by NADPH oxidase. J Mol Cell Cardiol 50(3):408–416. doi:10.1016/j.yjmcc.2010.12.018 PubMedPubMed CentralView ArticleGoogle Scholar
  32. Forstermann U, Sessa WC (2012) Nitric oxide synthases: regulation and function. Eur Heart J 33(7):829–837a-d. doi:10.1093/eurheartj/ehr304 PubMedView ArticleGoogle Scholar
  33. Dimmeler S, Zeiher AM (2000) Reactive oxygen species and vascular cell apoptosis in response to angiotensin II and pro-atherosclerotic factors. Regul Pept 90(1–3):19–25PubMedView ArticleGoogle Scholar
  34. Rodriguez MJ, Saura J, Billett EE, Finch CC, Mahy N (2001) Cellular localization of monoamine oxidase A and B in human tissues outside of the central nervous system. Cell Tissue Res 304(2):215–220PubMedView ArticleGoogle Scholar
  35. Huang YH, Ito A, Arai R (2005) Immunohistochemical localization of monoamine oxidase type B in pancreatic islets of the rat. J Histochem Cytochem Off J Histochem Soc 53(9):1149–1158. doi:10.1369/jhc.5A6658.2005 View ArticleGoogle Scholar
  36. Pizzinat N, Copin N, Vindis C, Parini A, Cambon C (1999) Reactive oxygen species production by monoamine oxidases in intact cells. Naunyn Schmiedeberg’s Arch Pharmacol 359(5):428–431View ArticleGoogle Scholar
  37. Kaludercic N, Carpi A, Menabo R, Di Lisa F, Paolocci N (2011) Monoamine oxidases (MAO) in the pathogenesis of heart failure and ischemia/reperfusion injury. Biochim Biophys Acta 1813(7):1323–1332. doi:10.1016/j.bbamcr.2010.09.010 PubMedView ArticleGoogle Scholar
  38. Santin Y, Sicard P, Vigneron F, Guilbeau-Frugier C, Dutaur M, Lairez O, Couderc B, Manni D, Korolchuk VI, Lezoualc’h F, Parini A, Mialet-Perez J (2016) Oxidative stress by monoamine oxidase-a impairs transcription factor EB activation and autophagosome clearance, leading to cardiomyocyte necrosis and heart failure. Antioxid Redox Signal. doi:10.1089/ars.2015.6522 PubMedGoogle Scholar
  39. Benson CA, Wong G, Tenorio G, Baker GB, Kerr BJ (2013) The MAO inhibitor phenelzine can improve functional outcomes in mice with established clinical signs in experimental autoimmune encephalomyelitis (EAE). Behav Brain Res 252:302–311. doi:10.1016/j.bbr.2013.06.019 PubMedView ArticleGoogle Scholar
  40. Namazi MR (2005) Phenytoin as a novel anti-vitiligo weapon. J Autoimmune Dis 2:11. doi:10.1186/1740-2557-2-11 PubMedPubMed CentralView ArticleGoogle Scholar
  41. Sies H (1997) Oxidative stress: oxidants and antioxidants. Exp Physiol 82(2):291–295PubMedView ArticleGoogle Scholar
  42. Xie H, Zhou F, Liu L, Zhu G, Li Q, Li C, Gao T (2016) Vitiligo: how do oxidative stress-induced autoantigens trigger autoimmunity? J Dermatol Sci 81(1):3–9. doi:10.1016/j.jdermsci.2015.09.003 PubMedView ArticleGoogle Scholar
  43. Salzano S, Checconi P, Hanschmann EM, Lillig CH, Bowler LD, Chan P, Vaudry D, Mengozzi M, Coppo L, Sacre S, Atkuri KR, Sahaf B, Herzenberg LA, Herzenberg LA, Mullen L, Ghezzi P (2014) Linkage of inflammation and oxidative stress via release of glutathionylated peroxiredoxin-2, which acts as a danger signal. Proc Natl Acad Sci USA 111(33):12157–12162. doi:10.1073/pnas.1401712111 PubMedPubMed CentralView ArticleGoogle Scholar
  44. Holmdahl R, Sareila O, Olsson LM, Backdahl L, Wing K (2016) Ncf1 polymorphism reveals oxidative regulation of autoimmune chronic inflammation. Immunol Rev 269(1):228–247. doi:10.1111/imr.12378 PubMedView ArticleGoogle Scholar
  45. Ahsan H, Ali A, Ali R (2003) Oxygen free radicals and systemic autoimmunity. Clin Exp Immunol 131(3):398–404PubMedPubMed CentralView ArticleGoogle Scholar
  46. Kienhofer D, Boeltz S, Hoffmann MH (2016) Reactive oxygen homeostasis—the balance for preventing autoimmunity. Lupus 25(8):943–954. doi:10.1177/0961203316640919 PubMedView ArticleGoogle Scholar
  47. Kolypetri P, King J, Larijani M, Carayanniotis G (2015) Genes and environment as predisposing factors in autoimmunity: acceleration of spontaneous thyroiditis by dietary iodide in NOD. H2(h4) mice. Int Rev Immunol 34(6):542–556. doi:10.3109/08830185.2015.1065828 PubMedView ArticleGoogle Scholar
  48. Braley-Mullen H, Yu S (2015) NOD.H-2h4 mice: an important and underutilized animal model of autoimmune thyroiditis and Sjogren’s syndrome. Adv Immunol 126:1–43. doi:10.1016/bs.ai.2014.11.001 PubMedView ArticleGoogle Scholar
  49. Burek CL, Rose NR (2008) Autoimmune thyroiditis and ROS. Autoimmun Rev 7(7):530–537. doi:10.1016/j.autrev.2008.04.006 PubMedView ArticleGoogle Scholar
  50. Sharma R, Traore K, Trush MA, Rose NR, Burek CL (2008) Intracellular adhesion molecule-1 up-regulation on thyrocytes by iodine of non-obese diabetic. H2(h4) mice is reactive oxygen species-dependent. Clin Exp Immunol 152(1):13–20. doi:10.1111/j.1365-2249.2008.03590.x PubMedPubMed CentralView ArticleGoogle Scholar
  51. Kolypetri P, Carayanniotis G (2014) Apoptosis of NOD. H2 h4 thyrocytes by low concentrations of iodide is associated with impaired control of oxidative stress. Thyroid Off J Am Thyroid Assoc 24(7):1170–1178. doi:10.1089/thy.2013.0676 View ArticleGoogle Scholar
  52. Duthoit C, Estienne V, Giraud A, Durand-Gorde JM, Rasmussen AK, Feldt-Rasmussen U, Carayon P, Ruf J (2001) Hydrogen peroxide-induced production of a 40 kDa immunoreactive thyroglobulin fragment in human thyroid cells: the onset of thyroid autoimmunity? Biochem J 360(Pt 3):557–562PubMedPubMed CentralView ArticleGoogle Scholar
  53. Poncin S, Colin IM, Decallonne B, Clinckspooor I, Many MC, Denef JF, Gerard AC (2010) N-acetylcysteine and 15 deoxy-{delta}12,14-prostaglandin J2 exert a protective effect against autoimmune thyroid destruction in vivo but not against interleukin-1{alpha}/interferon {gamma}-induced inhibitory effects in thyrocytes in vitro. Am J Pathol 177(1):219–228. doi:10.2353/ajpath.2010.091253 PubMedPubMed CentralView ArticleGoogle Scholar
  54. Ates I, Yilmaz FM, Altay M, Yilmaz N, Berker D, Guler S (2015) The relationship between oxidative stress and autoimmunity in Hashimoto’s thyroiditis. Eur J Endocrinol Eur Fed Endocr Soc 173(6):791–799. doi:10.1530/eje-15-0617 View ArticleGoogle Scholar
  55. Baser H, Can U, Baser S, Yerlikaya FH, Aslan U, Hidayetoglu BT (2015) Assesment of oxidative status and its association with thyroid autoantibodies in patients with euthyroid autoimmune thyroiditis. Endocrine 48(3):916–923. doi:10.1007/s12020-014-0399-3 PubMedView ArticleGoogle Scholar
  56. Ruggeri RM, Vicchio TM, Cristani M, Certo R, Caccamo D, Alibrandi A, Giovinazzo S, Saija A, Campenni A, Trimarchi F, Gangemi S (2016) Oxidative stress and advanced glycation end products in hashimoto’s thyroiditis. Thyroid Off J Am Thyroid Assoc 26(4):504–511. doi:10.1089/thy.2015.0592 View ArticleGoogle Scholar
  57. Zhu H, Li YR (2012) Oxidative stress and redox signaling mechanisms of inflammatory bowel disease: updated experimental and clinical evidence. Exp Biol Med (Maywood, NJ) 237(5):474–480. doi:10.1258/ebm.2011.011358 View ArticleGoogle Scholar
  58. Graff LA, Walker JR, Bernstein CN (2009) Depression and anxiety in inflammatory bowel disease: a review of comorbidity and management. Inflamm Bowel Dis 15(7):1105–1118. doi:10.1002/ibd.20873 PubMedView ArticleGoogle Scholar
  59. Mikocka-Walus AA, Turnbull DA, Moulding NT, Wilson IG, Andrews JM, Holtmann GJ (2006) Antidepressants and inflammatory bowel disease: a systematic review. Clin Pract Epidemiol Ment Health CP EMH 2:24. doi:10.1186/1745-0179-2-24 PubMedView ArticleGoogle Scholar
  60. Kast RE (1998) Crohn’s disease remission with phenelzine treatment. Gastroenterology 115(4):1034–1035PubMedView ArticleGoogle Scholar
  61. Magro F, Vieira-Coelho MA, Fraga S, Serrao MP, Veloso FT, Ribeiro T, Soares-da-Silva P (2002) Impaired synthesis or cellular storage of norepinephrine, dopamine, and 5-hydroxytryptamine in human inflammatory bowel disease. Dig Dis Sci 47(1):216–224PubMedView ArticleGoogle Scholar
  62. Gilgun-Sherki Y, Melamed E, Offen D (2004) The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy. J Neurol 251(3):261–268. doi:10.1007/s00415-004-0348-9 PubMedView ArticleGoogle Scholar
  63. Oliveira SR, Kallaur AP, Reiche EM, Kaimen-Maciel DR, Panis C, Lozovoy MA, Morimoto HK, Maes M, Dichi I, Simao AN (2016) Albumin and protein oxidation are predictors that differentiate relapsing-remitting from progressive clinical forms of multiple sclerosis. Mol Neurobiol. doi:10.1007/s12035-016-9860-z Google Scholar
  64. Gonsette RE (2008) Neurodegeneration in multiple sclerosis: the role of oxidative stress and excitotoxicity. J Neurol Sci 274(1–2):48–53. doi:10.1016/j.jns.2008.06.029 PubMedView ArticleGoogle Scholar
  65. Ortiz GG, Pacheco-Moises FP, Bitzer-Quintero OK, Ramirez-Anguiano AC, Flores-Alvarado LJ, Ramirez-Ramirez V, Macias-Islas MA, Torres-Sanchez ED (2013) Immunology and oxidative stress in multiple sclerosis: clinical and basic approach. Clin Dev Immunol 2013:708659. doi:10.1155/2013/708659 PubMedPubMed CentralView ArticleGoogle Scholar
  66. Fiorini A, Koudriavtseva T, Bucaj E, Coccia R, Foppoli C, Giorgi A, Schinina ME, Di Domenico F, De Marco F, Perluigi M (2013) Involvement of oxidative stress in occurrence of relapses in multiple sclerosis: the spectrum of oxidatively modified serum proteins detected by proteomics and redox proteomics analysis. PLoS One 8(6):e65184. doi:10.1371/journal.pone.0065184 PubMedPubMed CentralView ArticleGoogle Scholar
  67. Fischer MT, Sharma R, Lim JL, Haider L, Frischer JM, Drexhage J, Mahad D, Bradl M, van Horssen J, Lassmann H (2012) NADPH oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury. Brain J Neurol 135(Pt 3):886–899. doi:10.1093/brain/aws012 View ArticleGoogle Scholar
  68. Schallreuter KU, Moore J, Wood JM, Beazley WD, Gaze DC, Tobin DJ, Marshall HS, Panske A, Panzig E, Hibberts NA (1999) In vivo and in vitro evidence for hydrogen peroxide (H2O2) accumulation in the epidermis of patients with vitiligo and its successful removal by a UVB-activated pseudocatalase. J Investig Dermatol Symp Proc Soc Investig Dermatol Inc Eur Soc Dermatol Res 4(1):91–96View ArticleGoogle Scholar
  69. Hann SK, Chang JH, Lee HS, Kim SM (2000) The classification of segmental vitiligo on the face. Yonsei Med J 41(2):209–212. doi:10.3349/ymj.2000.41.2.209 PubMedView ArticleGoogle Scholar
  70. Schallreuter KU, Wood JM, Ziegler I, Lemke KR, Pittelkow MR, Lindsey NJ, Gutlich M (1994) Defective tetrahydrobiopterin and catecholamine biosynthesis in the depigmentation disorder vitiligo. Biochim Biophys Acta 1226(2):181–192PubMedView ArticleGoogle Scholar
  71. Schallreuter KU, Wood JM, Pittelkow MR, Buttner G, Swanson N, Korner C, Ehrke C (1996) Increased monoamine oxidase A activity in the epidermis of patients with vitiligo. Arch Dermatol Res 288(1):14–18PubMedView ArticleGoogle Scholar
  72. Laddha NC, Dwivedi M, Mansuri MS, Singh M, Gani AR, Yeola AP, Panchal VN, Khan F, Dave DJ, Patel A, Madhavan SE, Gupta R, Marfatia Z, Marfatia YS, Begum R (2014) Role of oxidative stress and autoimmunity in onset and progression of vitiligo. Exp Dermatol 23(5):352–353. doi:10.1111/exd.12372 PubMedView ArticleGoogle Scholar
  73. Schallreuter KU, Wood JM, Berger J (1991) Low catalase levels in the epidermis of patients with vitiligo. J Invest Dermatol 97(6):1081–1085PubMedView ArticleGoogle Scholar
  74. Sravani PV, Babu NK, Gopal KV, Rao GR, Rao AR, Moorthy B, Rao TR (2009) Determination of oxidative stress in vitiligo by measuring superoxide dismutase and catalase levels in vitiliginous and non-vitiliginous skin. Indian J Dermatol Venereol Leprol 75(3):268–271. doi:10.4103/0378-6323.48427 PubMedView ArticleGoogle Scholar
  75. Farahi-Jahromy A, Fallahzadeh MK, Ashkani-Esfahani S, Hamidizadeh N, Ghavipisheh M, Namazi MR (2014) Decreased glucose-6-phosphate dehydrogenase levels in vitiligo patients: further evidence of oxidative stress. Adv Biomed Res 3:34. doi:10.4103/2277-9175.124686 PubMedPubMed CentralView ArticleGoogle Scholar
  76. Jian Z, Li K, Liu L, Zhang Y, Zhou Z, Li C, Gao T (2011) Heme oxygenase-1 protects human melanocytes from H2O2-induced oxidative stress via the Nrf2-ARE pathway. J Invest Dermatol 131(7):1420–1427. doi:10.1038/jid.2011.56 PubMedView ArticleGoogle Scholar
  77. Domej W, Oettl K, Renner W (2014) Oxidative stress and free radicals in COPD–implications and relevance for treatment. Int J Chronic Obstr Pulm Dis 9:1207–1224. doi:10.2147/copd.s51226 View ArticleGoogle Scholar
  78. Hitchon CA, El-Gabalawy HS (2004) Oxidation in rheumatoid arthritis. Arthritis Res Ther 6(6):265–278. doi:10.1186/ar1447 PubMedPubMed CentralView ArticleGoogle Scholar
  79. Staron A, Makosa G, Koter-Michalak M (2012) Oxidative stress in erythrocytes from patients with rheumatoid arthritis. Rheumatol Int 32(2):331–334. doi:10.1007/s00296-010-1611-2 PubMedView ArticleGoogle Scholar
  80. Mapp PI, Grootveld MC, Blake DR (1995) Hypoxia, oxidative stress and rheumatoid arthritis. Br Med Bull 51(2):419–436PubMedGoogle Scholar
  81. Newkirk MM, Goldbach-Mansky R, Lee J, Hoxworth J, McCoy A, Yarboro C, Klippel J, El-Gabalawy HS (2003) Advanced glycation end-product (AGE)-damaged IgG and IgM autoantibodies to IgG-AGE in patients with early synovitis. Arthritis Res Ther 5(2):R82–R90PubMedPubMed CentralView ArticleGoogle Scholar
  82. Ostrakhovitch EA, Afanas’ev IB (2001) Oxidative stress in rheumatoid arthritis leukocytes: suppression by rutin and other antioxidants and chelators. Biochem Pharmacol 62(6):743–746PubMedView ArticleGoogle Scholar
  83. Davies MJ, Hawkins CL, Pattison DI, Rees MD (2008) Mammalian heme peroxidases: from molecular mechanisms to health implications. Antioxid Redox Signal 10(7):1199–1234. doi:10.1089/ars.2007.1927 PubMedView ArticleGoogle Scholar
  84. Cacciapaglia F, Anelli MG, Rizzo D, Morelli E, Scioscia C, Mazzotta D, Iannone F, Lapadula G (2015) Influence of TNF-alpha inhibition on oxidative stress of rheumatoid arthritis patients. Reumatismo 67(3):97–102. doi:10.4081/reumatismo.2015.829 PubMedView ArticleGoogle Scholar
  85. Jia Z, He J (2016) Paeoniflorin ameliorates rheumatoid arthritis in rat models through oxidative stress, inflammation and cyclooxygenase 2. Exp Ther Med 11(2):655–659. doi:10.3892/etm.2015.2908 PubMedGoogle Scholar
  86. Umar S, Zargan J, Umar K, Ahmad S, Katiyar CK, Khan HA (2012) Modulation of the oxidative stress and inflammatory cytokine response by thymoquinone in the collagen induced arthritis in Wistar rats. Chem Biol Interact 197(1):40–46. doi:10.1016/j.cbi.2012.03.003 PubMedView ArticleGoogle Scholar
  87. van der Toorn M, Rezayat D, Kauffman HF, Bakker SJ, Gans RO, Koeter GH, Choi AM, van Oosterhout AJ, Slebos DJ (2009) Lipid-soluble components in cigarette smoke induce mitochondrial production of reactive oxygen species in lung epithelial cells. Am J Physiol Lung Cell Mol Physiol 297(1):L109–L114. doi:10.1152/ajplung.90461.2008 PubMedPubMed CentralView ArticleGoogle Scholar
  88. MacNee W (2001) Oxidative stress and lung inflammation in airways disease. Eur J Pharmacol 429(1–3):195–207PubMedView ArticleGoogle Scholar
  89. Repine JE, Bast A, Lankhorst I (1997) Oxidative stress in chronic obstructive pulmonary disease. Oxidative Stress Study Group. Am J Respir Crit Care Med 156(2 Pt 1):341–357. doi:10.1164/ajrccm.156.2.9611013 PubMedView ArticleGoogle Scholar
  90. Florou AN, Gkiozos IC, Tsagouli SK, Souliotis KN, Syrigos KN (2014) Clinical significance of smoking cessation in subjects with cancer: a 30-year review. Respir Care 59(12):1924–1936. doi:10.4187/respcare.02559 PubMedView ArticleGoogle Scholar
  91. Sasco AJ, Secretan MB, Straif K (2004) Tobacco smoking and cancer: a brief review of recent epidemiological evidence. Lung Cancer (Amsterdam, Netherlands) 45(Suppl 2):S3–S9. doi:10.1016/j.lungcan.2004.07.998 View ArticleGoogle Scholar
  92. Boyko EJ, Perera DR, Koepsell TD, Keane EM, Inui TS (1988) Effects of cigarette smoking on the clinical course of ulcerative colitis. Scand J Gastroenterol 23(9):1147–1152PubMedView ArticleGoogle Scholar
  93. Calabrese E, Yanai H, Shuster D, Rubin DT, Hanauer SB (2012) Low-dose smoking resumption in ex-smokers with refractory ulcerative colitis. J Crohn’s Colitis 6(7):756–762. doi:10.1016/j.crohns.2011.12.010 View ArticleGoogle Scholar
  94. Fraga XF, Vergara M, Medina C, Casellas F, Bermejo B, Malagelada JR (1997) Effects of smoking on the presentation and clinical course of inflammatory bowel disease. Eur J Gastroenterol Hepatol 9(7):683–687PubMedView ArticleGoogle Scholar
  95. Mokbel M, Carbonnel F, Beaugerie L, Gendre JP, Cosnes J (1998) Effect of smoking on the long-term course of ulcerative colitis. Gastroenterol Clin Biol 22(11):858–862PubMedGoogle Scholar
  96. Schmeltz LR, Blevins TC, Aronoff SL, Ozer K, Leffert JD, Goldberg MA, Horowitz BS, Bertenshaw RH, Troya P, Cohen AE, Lanier RK, Ct Wright (2014) Anatabine supplementation decreases thyroglobulin antibodies in patients with chronic lymphocytic autoimmune (Hashimoto’s) thyroiditis: a randomized controlled clinical trial. J Clin Endocrinol Metab 99(1):E137–E142. doi:10.1210/jc.2013-2951 PubMedView ArticleGoogle Scholar
  97. Dorn HF (1959) Tobacco consumption and mortality from cancer and other diseases. Public Health Rep 74(7):581–593PubMedPubMed CentralView ArticleGoogle Scholar
  98. Thiriez C, Villafane G, Grapin F, Fenelon G, Remy P, Cesaro P (2011) Can nicotine be used medicinally in Parkinson’s disease? Expert Rev Clin Pharmacol 4(4):429–436. doi:10.1586/ecp.11.27 PubMedView ArticleGoogle Scholar
  99. Shao D, Oka S, Brady CD, Haendeler J, Eaton P, Sadoshima J (2012) Redox modification of cell signaling in the cardiovascular system. J Mol Cell Cardiol 52(3):550–558. doi:10.1016/j.yjmcc.2011.09.009 PubMedView ArticleGoogle Scholar
  100. Perricone C, Versini M, Ben-Ami D, Gertel S, Watad A, Segel MJ, Ceccarelli F, Conti F, Cantarini L, Bogdanos DP, Antonelli A, Amital H, Valesini G, Shoenfeld Y (2016) Smoke and autoimmunity: the fire behind the disease. Autoimmun Rev 15(4):354–374. doi:10.1016/j.autrev.2016.01.001 PubMedView ArticleGoogle Scholar
  101. Tsai CC, Cheng CY, Liu CY, Kao SC, Kau HC, Hsu WM, Wei YH (2009) Oxidative stress in patients with Graves’ ophthalmopathy: relationship between oxidative DNA damage and clinical evolution. Eye (London, England) 23(8):1725–1730. doi:10.1038/eye.2008.310 View ArticleGoogle Scholar
  102. Cao C, Lai T, Li M, Zhou H, Lv D, Deng Z, Ying S, Chen Z, Li W, Shen H (2016) Smoking-promoted oxidative DNA damage response is highly correlated to lung carcinogenesis. Oncotarget. doi:10.18632/oncotarget.7810 Google Scholar
  103. Steinmaus C, Miller MD, Howd R (2007) Impact of smoking and thiocyanate on perchlorate and thyroid hormone associations in the 2001–2002 national health and nutrition examination survey. Environ Health Perspect 115(9):1333–1338. doi:10.1289/ehp.10300 PubMedPubMed CentralView ArticleGoogle Scholar
  104. Pathak KV, Bellamri M, Wang Y, Langouet S, Turesky RJ (2015) 2-Amino-9H-pyrido[2,3-b]indole (AalphaC) adducts and thiol oxidation of serum albumin as potential biomarkers of tobacco smoke. J Biol Chem 290(26):16304–16318. doi:10.1074/jbc.M115.646539 PubMedPubMed CentralView ArticleGoogle Scholar
  105. Fowler JS, Volkow ND, Wang GJ, Pappas N, Logan J, Shea C, Alexoff D, MacGregor RR, Schlyer DJ, Zezulkova I, Wolf AP (1996) Brain monoamine oxidase A inhibition in cigarette smokers. Proc Natl Acad Sci USA 93(24):14065–14069PubMedPubMed CentralView ArticleGoogle Scholar
  106. Herraiz T, Chaparro C (2005) Human monoamine oxidase is inhibited by tobacco smoke: beta-carboline alkaloids act as potent and reversible inhibitors. Biochem Biophys Res Commun 326(2):378–386. doi:10.1016/j.bbrc.2004.11.033 PubMedView ArticleGoogle Scholar
  107. Leroy C, Bragulat V, Berlin I, Gregoire MC, Bottlaender M, Roumenov D, Dolle F, Bourgeois S, Penttila J, Artiges E, Martinot JL, Trichard C (2009) Cerebral monoamine oxidase A inhibition in tobacco smokers confirmed with PET and [11C]befloxatone. J Clin Psychopharmacol 29(1):86–88. doi:10.1097/JCP.0b013e31819e98f PubMedView ArticleGoogle Scholar
  108. Hogg RC (2016) Contribution of monoamine oxidase inhibition to tobacco dependence: a review of the evidence. Nicotine Tob Res Off J Soc Res Nicotine Tob 18(5):509–523. doi:10.1093/ntr/ntv245 View ArticleGoogle Scholar
  109. Khalil AA, Davies B, Castagnoli N Jr (2006) Isolation and characterization of a monoamine oxidase B selective inhibitor from tobacco smoke. Bioorgan Med Chem 14(10):3392–3398. doi:10.1016/j.bmc.2005.12.057 View ArticleGoogle Scholar
  110. Malczewska-Jaskola K, Jasiewicz B, Mrowczynska L (2016) Nicotine alkaloids as antioxidant and potential protective agents against in vitro oxidative haemolysis. Chem Biol Interact 243:62–71. doi:10.1016/j.cbi.2015.11.030 PubMedView ArticleGoogle Scholar

Copyright

© The Author(s) 2016

Advertisement